Back to search

Peptide record

TPDB04540

Nisin Z Antibacterial Anticancer Antifungal Antiparasitic standard
34 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB04540
Nisin Z
Antibacterial Anticancer Antifungal Antiparasitic
Anti-infective peptides Cancer-related peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept
standard
No
A 34-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK
Physicochemical Analysis
C141H245N41O46S7
RDEQFWY
CT
3475.16
8.48
4
0
10
+3
2.49
0.406
71.76
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
250
7.19
16
Residue Composition
number
2
A
0
R
2
N
0
D
5
C
0
E
0
Q
3
G
1
H
3
I
2
L
3
K
2
M
0
F
1
P
4
S
5
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 0 N: 2 D: 0 C: 5 E: 0 Q: 0 G: 3 H: 1 I: 3 L: 2 K: 3 M: 2 F: 0 P: 1 S: 4 T: 5 W: 0 Y: 0 V: 1
Chemical Descriptors
34
C141H245N41O46S7
3475.16
8.48
+3
2.49
0.406
Free
L
Linear
Free
Antimicrobial and Anticancer
Lactococcus lactis
Evidence Records 17 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.02 µg/mL

Target

L. lactis MG1363

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6
Evidence 2 Activity

Activity

MIC
Antibacterial
1.5-12.5 µg/mL

Target

L. monocytogenes LMG10470 or TT82E or LK132

Source & Reference

dbAMP DRAMP

Other

active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml
Evidence 3 Activity

Activity

MIC
Antibacterial
6.25 µg/mL

Target

B. cereus CH-85

Source & Reference

dbAMP DRAMP

Other

G1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG1
Evidence 4 Activity

Activity

MIC
Antibacterial
6.25 µg/mL

Target

Staphylococcus aureus LMG10147 or LMG15975 or MRSA

Source & Reference

dbAMP DRAMP

Other

ogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al.,
Evidence 5 Activity

Activity

MIC
Antibacterial
3.13 µg/mL

Target

E. faecium LMG11423 or LMG16003 or LMG16216

Source & Reference

dbAMP DRAMP

Other

reus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al., 2024 . Antivirus: Nisin was found to interact with the SARS-CoV-2
Evidence 6 Activity

Activity

IC50
IC50 = 188.5 ± 8.7 µM
Anticancer
188.5

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 7 Activity

Activity

60% LDH release at 60 µM
Anticancer

Target

Skin Cancer
A-375
Skin

Assay & Model

LDH leakage assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2018
Evidence 8 Activity

Activity

MIC
Antifungal
0.02 µg/mL

Target

L. lactis MG1363

Source & Reference

dbAMP DRAMP Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6
Evidence 9 Activity

Activity

MIC
Antifungal
1.5-12.5 µg/mL

Target

L. monocytogenes LMG10470 or TT82E or LK132

Source & Reference

dbAMP DRAMP Antifungipept

Other

active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml
Evidence 10 Activity

Activity

MIC
Antifungal
6.25 µg/mL

Target

B. cereus CH-85

Source & Reference

dbAMP DRAMP Antifungipept

Other

G1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG1
Evidence 11 Activity

Activity

MIC
Antifungal
6.25 µg/mL

Target

Staphylococcus aureus LMG10147 or LMG15975 or MRSA

Source & Reference

dbAMP DRAMP Antifungipept

Other

ogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al.,
Evidence 12 Activity

Activity

MIC
Antifungal
3.13 µg/mL

Target

E. faecium LMG11423 or LMG16003 or LMG16216

Source & Reference

dbAMP DRAMP Antifungipept

Other

reus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al., 2024 . Antivirus: Nisin was found to interact with the SARS-CoV-2
Evidence 13 Activity

Activity

MIC
Antiparasitic
0.02 µg/mL

Target

L. lactis MG1363

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6
Evidence 14 Activity

Activity

MIC
Antiparasitic
1.5-12.5 µg/mL

Target

L. monocytogenes LMG10470 or TT82E or LK132

Source & Reference

DRAMP

Other

active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml
Evidence 15 Activity

Activity

MIC
Antiparasitic
6.25 µg/mL

Target

B. cereus CH-85

Source & Reference

DRAMP

Other

G1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG1
Evidence 16 Activity

Activity

MIC
Antiparasitic
6.25 µg/mL

Target

Staphylococcus aureus LMG10147 or LMG15975 or MRSA

Source & Reference

DRAMP

Other

ogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al.,
Evidence 17 Activity

Activity

MIC
Antiparasitic
3.13 µg/mL

Target

E. faecium LMG11423 or LMG16003 or LMG16216

Source & Reference

DRAMP

Other

reus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al., 2024 . Antivirus: Nisin was found to interact with the SARS-CoV-2